Alzamend Neuro (NASDAQ:ALZN) Trading Up 3.6% – What’s Next?

Alzamend Neuro, Inc. (NASDAQ:ALZN)’s stock price shot up 3.6% on Thursday . The stock traded as high as $1.19 and last traded at $1.16. 371,030 shares traded hands during trading, an increase of 22% from the average session volume of 304,163 shares. The stock had previously closed at $1.12.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.00.

Alzamend Neuro Trading Up 3.6%

The firm has a 50 day moving average of $1.15 and a 200-day moving average of $1.59. The company has a market cap of $4.41 million, a P/E ratio of -0.54 and a beta of 0.14.

Insider Activity

In related news, Director Milton C. Ault III bought 108,388 shares of the stock in a transaction dated Tuesday, April 14th. The shares were purchased at an average price of $1.00 per share, with a total value of $108,388.00. Following the completion of the acquisition, the director owned 116,648 shares of the company’s stock, valued at $116,648. This represents a 1,312.20% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is currently owned by insiders.

Institutional Trading of Alzamend Neuro

An institutional investor recently raised its stake in Alzamend Neuro stock. DRW Securities LLC raised its stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 116,319 shares of the company’s stock after purchasing an additional 25,074 shares during the period. DRW Securities LLC owned 3.06% of Alzamend Neuro worth $212,000 as of its most recent filing with the Securities & Exchange Commission. 49.61% of the stock is owned by institutional investors and hedge funds.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.